Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

Core Insights - Beam Therapeutics is expanding its pipeline with a new program, BEAM-304, aimed at treating phenylketonuria (PKU), a rare metabolic disorder affecting approximately 20,000 individuals in the U.S. [1][3] - The company anticipates filing an Investigational New Drug (IND) application for BEAM-304 in 2026 and expects to report updated Phase 1/2 data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) by Q1 2026 [1][5][11] - A strategic financing agreement with Sixth Street provides up to $500 million in long-term, non-dilutive capital to support the anticipated launch of risto-cel for Sickle Cell Disease (SCD), with a U.S. Biologics License Application (BLA) submission expected by year-end 2026 [1][11] Financial Performance - As of December 31, 2025, Beam's cash, cash equivalents, and marketable securities totaled $1.25 billion, an increase from $850.7 million in 2024 [18][21] - Research and Development (R&D) expenses for Q4 2025 were $99.3 million, compared to $101.4 million in Q4 2024, while full-year R&D expenses rose to $409.6 million from $367.6 million [18][23] - General and Administrative (G&A) expenses for Q4 2025 were $32.3 million, up from $28.7 million in Q4 2024, with full-year G&A expenses totaling $113.8 million compared to $111.5 million in 2024 [18][23] Clinical Development - BEAM-304 utilizes Beam's proprietary base editing technology and lipid nanoparticle (LNP) delivery to correct mutations in the phenylalanine hydroxylase (PAH) gene, aiming to reduce toxic phenylalanine levels and normalize diet for PKU patients [3][4] - The initial clinical development of BEAM-304 will focus on patients with the R408W mutation, with plans to expand to additional mutations [6][11] - The company is also advancing BEAM-302 for AATD and BEAM-301 for Glycogen Storage Disease type Ia (GSDIa), with initial clinical data expected in 2026 [8][9][11] Strategic Partnerships - Beam has entered a strategic financing agreement with Sixth Street, which includes a $500 million senior secured credit facility to support the launch of risto-cel [11] - In December 2025, Pfizer opted for an exclusive worldwide license for a liver-targeted development candidate from Beam, which will involve milestone payments and a potential co-development agreement [11][18]

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) - Reportify